Key result
Catheter ablation is linked to ~33-point lower AF recurrence in hypertrophic cardiomyopathy versus no rhythm control.
Why the study?
The short-term natural history of atrial fibrillation, including recurrence and treatment effectiveness, in hypertrophic cardiomyopathy remains poorly characterized.
Do rhythm control strategies (antiarrhythmic drugs or catheter ablation) reduce atrial fibrillation recurrence compared to no rhythm control in patients with hypertrophic cardiomyopathy and first-detected AF?
Cohort (n=149)
No
Do rhythm control strategies (antiarrhythmic drugs or catheter ablation) reduce atrial fibrillation recurrence compared to no rhythm control in patients with hypertrophic cardiomyopathy and first-detected AF?
Atrial fibrillation recurrence is highly prevalent in patients with hypertrophic cardiomyopathy following a first detected episode, though catheter ablation is associated with lower recurrence rates compared to antiarrhythmic drugs or observation.
Answers are grounded in this paper and cite their sources.
High AF recurrence after first episode in HCM warrants close monitoring; leaves open optimal rhythm-control strategy pending prospective trials.
Background: Atrial fibrillation (AF) is the most common sustained arrhythmia in hypertrophic cardiomyopathy (HCM), occurring in 20–25% of patients and associated with increased morbidity, stroke risk, and symptom burden. Despite this substantial clinical impact, the understanding of the short-term natural history of AF, including recurrence and the effectiveness of treatment strategies in HCM, remains poorly characterized. Methods: We assessed 2016 patients referred to Lahey Hospital and Medical Center for the diagnosis and subspecialty management of HCM, of whom 341 (17%) had a remote history of AF (≥5 years), and 149 (7%) had AF episodes initially detected between January 2020 and June 2025. These 149 patients were included in this retrospective analysis to allow comprehensive short-term assessment of AF recurrence, treatment interventions, and clinical outcomes from first detected AF utilizing contemporary treatments. Results: AF was first detected at a median age of 63 years (IQR 54–70); 63% were male. Most AF episodes (87%) were symptomatic at presentation. Among 146 patients who converted to sinus rhythm, AF recurred in 80 (54%) at a median of 171 days (IQR 53–278; 29% at 6 months, 43% at 12 months). In patients not undergoing rhythm control after first detected AF episode, 60% had spontaneous recurrence (29% at 6 months, 48% at 1 year), while recurrence rates after antiarrhythmic drug (AAD) initiation were 44% (28% at 6 months, 37.5% at 1 year), and after catheter ablation were 27% (9.8% at 6 months, 18% at 1 year). At last follow-up, 1.9 years (IQR 1.2–2.6 years) from first detected AF episode, 133 of 149 patients (89%) were in sinus rhythm. Seven patients (4.7%) died at a median of 1.16 years (IQR 0.74–1.62) after their first detected AF; estimated survival was 98.6% at 1 year and 96.0% at 3 years. Conclusions: AF recurrence occurs at high rates after the initial detected AF episode in HCM regardless of rhythm-control strategy or AAD use. Catheter ablation was associated with lower recurrence rates. These findings characterize the relapsing natural history of HCM-associated AF and underscore the need for further studies to optimize rhythm-control strategies in this population.
No takes yet. Share an insight, caveat, or question.
Wanderley et al. (2026) conducted a cohort in Hypertrophic Cardiomyopathy with first detected Atrial Fibrillation (n=149). Catheter ablation or antiarrhythmic drugs vs. No rhythm control was evaluated on Atrial fibrillation recurrence. Catheter ablation and antiarrhythmic drugs were associated with atrial fibrillation recurrence rates of 27% and 44% respectively, compared to 60% with no rhythm control in hypertrophic cardiomyopathy.
Synapse has enriched 10 related papers. Consider them for comparative context: